> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Says Lung Cancer Trial Misses Endpoint
- URL: https://www.fdaweb.com/astrazeneca-says-lung-cancer-trial-misses-endpoint/
- Published: 2016-08-10T12:00:00.000Z
- Updated: 2026-09-14T21:23:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5136468

AstraZeneca has reported disappointing results from a Phase 3 trial (SELECT-1) of its MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as second-line treatment in patients with *KRAS* mutation-positive locally-advanced or metastatic non-small cell lung cancer. “The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS),” the company says. The adverse event profiles for selumetinib and docetaxel were consistent with what has been previously seen, it says. SELECT-1 is an international trial with 510 randomized patients in over 200 centers. Patients either received selumetinib (75mg, orally, twice daily) or placebo in combination with docetaxel.